Investment Services News

Microsize Announces a Strategic Investment into The Solubility Company to Accelerate the US Expansion of a Novel

Microsize Announces a Strategic Investment into The Solubility Company to Accelerate the US Expansion of a Novel

Microsize announced the strategic investment and partnership with Helsinki-based The Solubility Company. Microsize’s investment accelerates plans for The Solubility Company to open a US-based solubility lab which will be located in Microsize’s facility in Quakertown PA. North American-based pharmaceutical companies will have direct access to the revolutionary AI-enabled Single Particle Analysis (SPA) technology to accurately measure solubility and dissolution rate with sample quantities as low as 1-2 milligrams. The proprietary SPA™ technology allows for fast, reliable, and continuous measurements of the dissolution process directly from powder samples using machine vision and advanced AI providing accurate solubility measurements much earlier in the developmental process than what is currently possible. The technology will benefit Microsize customers who today utilize Microsize services to enhance solubility and bioavailability of drug candidates using particle size engineering including micronization and nanomilling.

Latest Fintech Interview: Global Fintech Interview with Paul Monk, Chief Executive Officer at Alpha Development

“a testament to The Solubility Company’s pioneering work in pharmaceutical analysis. The partnership with Microsize presents an exciting opportunity to transform the drug development process for pharma clients.”

TJ Higley, CEO of Microsize, added: “We couldn’t be more excited to support The Solubility Company in the expansion of this powerful technology to customers stateside. While operating as a discreet and fully autonomous entity within our facilities, the synergistic value of The Solubility Company’s SPA™ technology to Microsize clients is meaningful.

Read More About Fintech Interview: Global Fintech Interview with Michael Rangel, Founder and CEO at Novo

This partnership should further streamline, speed to market for our clients by combining early answers in solubility alongside our full suite of solid-state characterization capabilities under one roof. Adding this type characterization in parallel with our particle engineering technologies, we can unlock immense value in developing the best drug product intermediate for our clients.

“The funding will fuel our strategic expansion into the US, our main market” said Dr. Sami Svanbäck, CEO of The Solubility Company. He further characterized the investment by leading industry experts as “a testament to The Solubility Company’s pioneering work in pharmaceutical analysis. The partnership with Microsize presents an exciting opportunity to transform the drug development process for pharma clients.”

Browse The Complete Interview About Fintech : Global Fintech Interview with Sankaet Pathak, CEO at Synapse

 [To share your insights with us, please write to sghosh@martechseries.com] 

Related posts

Third Edition of the Complimentary Wolters Kluwer Audit Talks LIVE Virtual Conference Takes Place June 2-3, 2020

Ironblocks Launches Blockchain-Native Security Solution for Web3 and DeFi Protocols

PR Newswire

Covr Financial Technologies and The Financial Architects Partners, LLC Launch Digital Partnership for Advanced Insurance Design for Financial Institutions

Fintech News Desk
1